Cargando…
Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation
The approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect the susceptibility profiles of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients. This 5-year, prospective, observational study tracked suscep...
Autores principales: | Keating, Claire L., Zuckerman, Jonathan B., Singh, Pradeep K., McKevitt, Matthew, Gurtovaya, Oksana, Bresnik, Mark, Marshall, Bruce C., Saiman, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092527/ https://www.ncbi.nlm.nih.gov/pubmed/33318007 http://dx.doi.org/10.1128/AAC.02327-20 |
Ejemplares similares
-
Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
por: Khan, Ayesha, et al.
Publicado: (2021) -
Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019) -
Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
por: Bhatnagar, Amelia, et al.
Publicado: (2021) -
A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals
por: Puzniak, Laura, et al.
Publicado: (2019) -
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
por: Daddario, Martha K, et al.
Publicado: (2010)